Other TKIs, such as gefitinib and erlotinib, target EGFR mutations in NSCLC, leading to improved progression-free survival and overall response rates in patients harboring sensitive EGFR mutations [59]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.